News and Trends 19 Aug 2022
Gilead to acquire remaining worldwide rights of breast cancer drug, Trodelvy
All of Everest Medicine's development and commercialization rights for a breast cancer drug called Trodelvy have been transferred to American…
Gilead
- Latest Posts
News and Trends 4 Mar 2021
Galapagos and Gilead Soldier On After Inflammatory Disease Flops
Clinical and regulatory setbacks have left the star biotech duo Gilead and Galapagos smarting and their stock value bruised in…
News and Trends 5 Oct 2020
Galapagos’ Arthritis Drug Approved in EU and Japan Amid US Rejection
The recent EU and Japan approvals of the rheumatoid arthritis drug filgotinib contrast with the FDA’s rejection in August. What…
News and Trends 8 Jul 2020
Remdesivir Becomes the First Covid-19 Treatment Approved in Europe
Remdesivir has received a one-year conditional marketing authorization from the European Commission due to the urgency of the Covid-19 pandemic,…
ADVERTISEMENT
News and Trends 15 Jul 2019
Gilead Pays Billions for Access to Galapagos’ Pipeline
Gilead has launched a 10-year collaboration with the Belgo-Dutch biotech Galapagos, paying at least €4.5B ($5.1B) for commercial rights to…
News and Trends 3 Jun 2019
Belgian and US Biotechs Team up to Reduce CAR T Side Effects
The diagnostics company Biocartis is collaborating with Kite Pharma to monitor the progress of CAR T-cell therapies in patients to…
News and Trends 3 Jan 2019
Austrian Biopharma Reaches First HIV Vaccine Milestone
Hookipa Pharma has reached its first milestone in a partnership deal with US-based CAR T pioneers Gilead Sciences to develop…
News and Trends 5 Jul 2017
Galapagos and Gilead Launch the Fifth New Trial for Filgotinib this Year
With the addition of uveitis, Galapagos and Gilead are raising to 10 the number of indications in filgotinib's clinical pipeline.…
News and Trends 14 Feb 2017
Dual HIV Therapy: GSK and Gilead Battle over Whose Drug is the Best
GSK announced Phase III results for dolutegravir, which could reduce triple HIV therapy down to two drugs, but Gilead is…
News and Trends 9 Dec 2016
Galapagos gets another Milestone Payment from Gilead
Galapagos is starting a new PhaseIIb/III clinical trial for ulcerative colitis that has triggered a €9.4M milestone payment from Gilead. Can…
News and Trends 25 Aug 2016
Galapagos Hangs On: Filgotinib enters Phase III for Rheumatoid Arthritis
After losing AbbVie as a partner, Galapagos has pressed on with Gilead in the development of filgotinib for rheumatoid arthritis.…
News and Trends 24 Aug 2016
While working on its HIV Cure, Gilead gives Europe an ‘HIV Vaccine’
Despite progress in HIV treatments and towards an HIV cure, the infection rate has risen to unprecedented levels in Europe.…
News and Trends 15 Aug 2016
Gilead licenses Danish Bispecific antibodies for the next HIV Cure
As an add-on to their previously secretive partnership, Genmab is now licensing its bispecific antibodies for Gilead's pursuit of an HIV…
News and Trends 23 Feb 2016
How could the HIV Field benefit from Gilead’s new €2M Research Grants?
The US Giant Gilead is opening a new program of Grants to fund the next generation of HIV research for 3-years.…
News and Trends 17 Feb 2016
After a Deal with Gilead, Galapagos is Still Doing Phase II Trials with AbbVie
Galapagos (Belgium) is moving forward with their cystic fibrosis drug candidate after promising Phase I results - and still in collaboration with…
News and Trends 18 Dec 2015
Finally! Galapagos New Mystery Partner to Replace AbbVie Revealed in €2Bn Deal
At last! We now know the fate of Galapagos Phase III Rheumatoid Arthritis drug after AbbVie's shocking abandonment. The Mystery…
ADVERTISEMENT
News and Trends 9 Nov 2015
A Group of French Medics are Questioning the Fastest-Growing Big Biotech in the World…
Approved drugs can always show bad signs once injected massively. Four physicians from Paris sent a letter to the New…
News and Trends 6 Jul 2015
After selling its company to Gilead, Martin Bonde joins Norwegian Vaccibody as CEO
Two weeks ago, I travelled through Denmark to interview 15 CEOs to film its biotech industry, Labiotech Tour Denmark. Amongst them was…
News and Trends 19 May 2015
Boehringer kindles NASH treatments with Pharmaxis’ drug acquisition
Does NASH mean anything to you? You should be vigilant about this market as it could be the source of next…
News and Trends 7 May 2015
Gilead acquired epigenetics-expert EpiTherapeutics
Gilead Sciences has acquired the small Danish biotech EpiTherapeutics for €57M. The epigenetics-expert has generated a library of small molecule…
